Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer. / Lima, Thiago S.; Souza, Luciano O.; Iglesias-Gato, Diego; Elversang, Johanna; Jørgensen, Flemming Steen; Kallunki, Tuula; Røder, Martin A.; Brasso, Klaus; Moreira, José M.A.
In: Frontiers in Pharmacology, Vol. 13, 869461, 2022.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer
AU - Lima, Thiago S.
AU - Souza, Luciano O.
AU - Iglesias-Gato, Diego
AU - Elversang, Johanna
AU - Jørgensen, Flemming Steen
AU - Kallunki, Tuula
AU - Røder, Martin A.
AU - Brasso, Klaus
AU - Moreira, José M.A.
N1 - Funding Information: TL, LS, DI-G, FJ, and TK were responsible for acquisition, formal analysis, and interpretation of data. JE, TK, MR, KB, and JM conceived the study and supervised the work. MR, KB, and JM were responsible for funding acquisition. TL, LS, DI-G, JE, FJ, TK, MR, KB, and JM drafted the manuscript or substantively revised it. All authors reviewed the results and approved the final version of the manuscript.
PY - 2022
Y1 - 2022
N2 - Docetaxel (DTX) was the first chemotherapeutic agent to demonstrate significant efficacy in the treatment of men with metastatic castration-resistant prostate cancer. However, response to DTX is generally short-lived, and relapse eventually occurs due to emergence of drug-resistance. We previously established two DTX-resistant prostate cancer cell lines, LNCaPR and C4-2BR, derived from the androgen‐dependent LNCaP cell line, and from the LNCaP lineage-derived androgen-independent C4-2B sub-line, respectively. Using an unbiased drug screen, we identify itraconazole (ITZ), an oral antifungal drug, as a compound that can efficiently re-sensitize drug-resistant LNCaPR and C4-2BR prostate cancer cells to DTX treatment. ITZ can re-sensitize multiple DTX-resistant cell models, not only in prostate cancer derived cells, such as PC-3 and DU145, but also in docetaxel-resistant breast cancer cells. This effect is dependent on expression of ATP-binding cassette (ABC) transporter protein ABCB1, also known as P-glycoprotein (P-gp). Molecular modeling of ITZ bound to ABCB1, indicates that ITZ binds tightly to the inward-facing form of ABCB1 thereby inhibiting the transport of DTX. Our results suggest that ITZ may provide a feasible approach to re-sensitization of DTX resistant cells, which would add to the life-prolonging effects of DTX in men with metastatic castration-resistant prostate cancer.
AB - Docetaxel (DTX) was the first chemotherapeutic agent to demonstrate significant efficacy in the treatment of men with metastatic castration-resistant prostate cancer. However, response to DTX is generally short-lived, and relapse eventually occurs due to emergence of drug-resistance. We previously established two DTX-resistant prostate cancer cell lines, LNCaPR and C4-2BR, derived from the androgen‐dependent LNCaP cell line, and from the LNCaP lineage-derived androgen-independent C4-2B sub-line, respectively. Using an unbiased drug screen, we identify itraconazole (ITZ), an oral antifungal drug, as a compound that can efficiently re-sensitize drug-resistant LNCaPR and C4-2BR prostate cancer cells to DTX treatment. ITZ can re-sensitize multiple DTX-resistant cell models, not only in prostate cancer derived cells, such as PC-3 and DU145, but also in docetaxel-resistant breast cancer cells. This effect is dependent on expression of ATP-binding cassette (ABC) transporter protein ABCB1, also known as P-glycoprotein (P-gp). Molecular modeling of ITZ bound to ABCB1, indicates that ITZ binds tightly to the inward-facing form of ABCB1 thereby inhibiting the transport of DTX. Our results suggest that ITZ may provide a feasible approach to re-sensitization of DTX resistant cells, which would add to the life-prolonging effects of DTX in men with metastatic castration-resistant prostate cancer.
KW - androgen independence
KW - cellular models
KW - docetaxel resistance
KW - drug repurposing
KW - metastatic castration-resistant prostate cancer
U2 - 10.3389/fphar.2022.869461
DO - 10.3389/fphar.2022.869461
M3 - Journal article
C2 - 35721223
AN - SCOPUS:85133250846
VL - 13
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
SN - 1663-9812
M1 - 869461
ER -
ID: 320354862